Form 4: Cocrystal Pharma Director Anthony Japour Reports Acquisition of Restricted Stock Units

Director Anthony Japour reports acquisition of restricted stock units in Cocrystal Pharma, Inc.

Summary

• On October 9, 2024, Anthony Japour, a director of Cocrystal Pharma, Inc., reported the acquisition of 14,924 restricted stock units (RSUs).
• One half of the RSUs are fully vested.
• The balance vesting in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date.
• Shares of common stock will be delivered to the Reporting Person promptly upon vesting, unless the Reporting Person elects to defer delivery.
• The RSUs were granted under the Issuer's 2015 Equity Incentive Plan and will vest in full upon a Change of Control as defined in such Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction related to executive compensation. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The vesting schedule of the RSUs incentivizes continued service from the director.
• Full vesting upon a change of control aligns the director's interests with those of the shareholders in such an event.

Future Outlook

The remaining RSUs will vest in eight equal quarterly installments on the last day of each quarter commencing with the quarter ending September 30, 2025, subject to continued services for the Company as of each applicable vesting date.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies.

Stakeholder Impact

• The granting of RSUs aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term performance.

Key Dates